[go: up one dir, main page]

CL2015003266A1 - Formulación estabilizada de pemetrexed. - Google Patents

Formulación estabilizada de pemetrexed.

Info

Publication number
CL2015003266A1
CL2015003266A1 CL2015003266A CL2015003266A CL2015003266A1 CL 2015003266 A1 CL2015003266 A1 CL 2015003266A1 CL 2015003266 A CL2015003266 A CL 2015003266A CL 2015003266 A CL2015003266 A CL 2015003266A CL 2015003266 A1 CL2015003266 A1 CL 2015003266A1
Authority
CL
Chile
Prior art keywords
pemetrexed
formulation
stabilized formulation
air space
container
Prior art date
Application number
CL2015003266A
Other languages
English (en)
Inventor
Young Joon Park
Myung Jin Shin
Hong Chul Jin
Ha Yong Choi
Nak Hyun Choi
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51867494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of CL2015003266A1 publication Critical patent/CL2015003266A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

UNA FORMULACION QUE COMPRENDE PEMETREXED O UNA SAL DEL MISMO COMO PRINCIPIO ACTIVO, N-ACETIL-L-CISTEINA Y CITRATO SODICO; Y FORMULACION DE PEMETREXED CARGADA EN UN RECIPIENTE SELLADO QUE COMPRENDE UN CONTENIDO DE GAS OXIGENO DEL 3% V/V O MENOR DENTRO DEL ESPACIO AEREO DEL RECIPIENTE, RESPECTO DEL VOLUMEN TOTAL DEL ESPACIO AEREO.
CL2015003266A 2013-05-08 2015-11-06 Formulación estabilizada de pemetrexed. CL2015003266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130052083A KR101485243B1 (ko) 2013-05-08 2013-05-08 안정화된 페메트렉시드 제제

Publications (1)

Publication Number Publication Date
CL2015003266A1 true CL2015003266A1 (es) 2016-04-22

Family

ID=51867494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003266A CL2015003266A1 (es) 2013-05-08 2015-11-06 Formulación estabilizada de pemetrexed.

Country Status (13)

Country Link
US (1) US9629844B2 (es)
EP (1) EP2995298B1 (es)
JP (1) JP6159879B2 (es)
KR (1) KR101485243B1 (es)
CN (1) CN105451717B (es)
BR (1) BR112015028124B1 (es)
CL (1) CL2015003266A1 (es)
ES (1) ES2890523T3 (es)
HK (1) HK1218076A1 (es)
MX (1) MX362807B (es)
PH (1) PH12015502542B1 (es)
RU (1) RU2636783C2 (es)
WO (1) WO2014182093A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101260636B1 (ko) * 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
WO2015050230A1 (ja) 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
JP6120766B2 (ja) * 2013-12-27 2017-04-26 富士フイルム株式会社 注射液製剤及びその製造方法
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
WO2016082714A1 (zh) * 2014-11-26 2016-06-02 台湾东洋药品工业股份有限公司 具有长期稳定性的不含抗氧化剂的药物注射溶液的制备方法
WO2016129000A1 (en) 2015-02-13 2016-08-18 Sun Pharmaceutical Industries Ltd Intravenous infusion dosage form
KR101919436B1 (ko) 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) * 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
JP6837895B2 (ja) * 2017-04-04 2021-03-03 日本化薬株式会社 医薬品溶液製剤の製造方法
US10507165B2 (en) 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
US10369077B2 (en) * 2017-05-31 2019-08-06 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using the same
US20200246263A1 (en) * 2017-08-29 2020-08-06 Fresenius Kabi Oncology Limited Stable liquid compositions of pemetrexed
MX2021005665A (es) * 2018-11-14 2021-09-23 Avm Biotechnology Llc Formulacion estable de glucocorticoide.
JPWO2021192471A1 (es) * 2020-03-24 2021-09-30
WO2023237093A1 (zh) * 2022-06-09 2023-12-14 上海云晟研新生物科技有限公司 培美曲塞二钠液体组合物、其制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
DE60103512T2 (de) 2000-02-04 2005-06-02 Eli Lilly And Co., Indianapolis Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l-cystein oder thioglykolsäure
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
KR100744917B1 (ko) * 2000-02-25 2007-08-01 일라이 릴리 앤드 캄파니 신규한 결정형의Ｎ-[4-[2-(2-아미노-4,7-디히드로-4-옥소-3Ｈ-피롤로[2,3-ｄ]피리미딘-5-일)에틸]벤조일]-Ｌ-글루탐산 및 이의 제조방법
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
ATE364402T1 (de) 2004-03-10 2007-07-15 Shimoda Biotech Pty Ltd Stabile injizierbare diclofenac- zubereitungen
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
US9655898B2 (en) * 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
KR101069128B1 (ko) 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
WO2013179248A1 (en) 2012-05-30 2013-12-05 Fresenius Kabi Oncology Ltd. Pharmaceutical compositions of pemetrexed
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제

Also Published As

Publication number Publication date
MX362807B (es) 2019-02-13
JP6159879B2 (ja) 2017-07-05
CN105451717A (zh) 2016-03-30
US9629844B2 (en) 2017-04-25
MX2015015356A (es) 2016-03-04
US20160120867A1 (en) 2016-05-05
ES2890523T3 (es) 2022-01-20
WO2014182093A1 (ko) 2014-11-13
RU2636783C2 (ru) 2017-11-28
CN105451717B (zh) 2018-05-22
HK1218076A1 (zh) 2017-02-03
EP2995298A1 (en) 2016-03-16
PH12015502542A1 (en) 2016-02-22
EP2995298A4 (en) 2017-01-25
EP2995298B1 (en) 2021-06-23
PH12015502542B1 (en) 2019-11-15
KR20140132621A (ko) 2014-11-18
BR112015028124A2 (pt) 2017-07-25
JP2016518404A (ja) 2016-06-23
RU2015149114A (ru) 2017-06-09
BR112015028124B1 (pt) 2023-02-28
KR101485243B1 (ko) 2015-01-21

Similar Documents

Publication Publication Date Title
CL2015003266A1 (es) Formulación estabilizada de pemetrexed.
MX2015005238A (es) Unidad de empaque de un producto farmacuetico, medico o cosmetico y un metodo de esterilizacion de un producto farmaceutico, medico o cosmetico que se puede colocar en la unidad de empaque.
PH12017501324B1 (en) Vapour provision system and cartridge therefor
MX2015012493A (es) Sistema de control de humedad para productos de madera.
PH12017500155A1 (en) Aerosol provision system
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
LT3216448T (lt) Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sisteminio poveikio veikliuosius agentus, būdai ir jų panaudojimas
MX2015017821A (es) Heterociclos bi-o triciclicos activos como plaguicidas con sustituyentes que contienen azufre.
DOP2015000006A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
AR098168A1 (es) Formulación estable de insulina glulisina
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
CL2015002786A1 (es) Aparato para dosis medida de sustancia de control del olor
MX2015011784A (es) Dispositivo de terapia para periimplantitis.
TWD189982S (zh) 注射裝置的容器
TWD164234S (zh) 香水瓶
MX2022000915A (es) Metodo para prolongar la viabilidad de esporas fungicas en formulaciones liquidas.
PH12015501602A1 (en) Agent for elevating nitric oxide concentration
EP2965809A4 (en) OXYGEN ABSORBING COMPOSITION AND FORM BODY AND PACKAGING THEREWITH
SG10201709595WA (en) Solutions for increasing the stability and shelf life of an organ and tissue preservation solution
MX345216B (es) Solucion oftalmica que contiene acido hialuronico o sal del mismo y propilenglicol.
AR103045A1 (es) Método para prolongar la viabilidad de esporas fúngicas en formulaciones líquidas
WO2015001524A3 (en) Stabilization of rose dedifferentiated cells
MX2016011448A (es) Envase.
MX356050B (es) Composicion farmaceutica acuosa con estabilidad mejorada.